Gene Therapy SPK-8011 Prevents Bleeds Up to 4 Years

Gene Therapy SPK-8011 Prevents Bleeds Up to 4 Years

300581

Gene Therapy SPK-8011 Prevents Bleeds Up to 4 Years

A single dose of Spark Therapeutics’ investigational gene therapy SPK-8011 safely and effectively prevented bleeding episodes and the use of clotting factor VIII (FVIII) for up to four years in men with hemophilia A, according to the latest data from a Phase 1/2 trial and its extension study. These benefits, observed so far in 16 of the 18 treated patients, were associated with sustained production of FVIII, the clotting factor missing in people with hemophilia…

You must be logged in to read/download the full post.